ellaOne

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
26-01-2024
Ciri produk Ciri produk (SPC)
26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
06-02-2015

Bahan aktif:

ulipristal

Boleh didapati daripada:

Laboratoire HRA Pharma

Kod ATC:

G03AD02

INN (Nama Antarabangsa):

ulipristal acetate

Kumpulan terapeutik:

Sex hormones and modulators of the genital system, , Emergency contraceptives

Kawasan terapeutik:

Contraception, Postcoital

Tanda-tanda terapeutik:

Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.

Ringkasan produk:

Revision: 30

Status kebenaran:

Authorised

Tarikh kebenaran:

2009-05-15

Risalah maklumat

                                37
B. PACKAGE LEAFLET
38
PACKAGE LEAFLET: INFORMATION FOR THE USER
ELLAONE 30 MG TABLET
Ulipristal acetate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your pharmacist, doctor or other
healthcare professional has told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your pharmacist, doctor, or other
healthcare professional.
This includes any possible side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What ellaOne is and what it is used for
2.
What you need to know before you take ellaOne
3.
How to take ellaOne
4.
Possible side effects
5.
How to store ellaOne
6.
Contents of the pack and other information
- Useful information about contraception
1.
WHAT ELLAONE IS AND WHAT IT IS USED FOR
ellaOne is an emergency contraceptive
ellaOne is a contraceptive intended to prevent pregnancy after
unprotected sex or if your contraceptive
method has failed. For example:
-
if you had sex without protection;
-
if your or your partner’s condom tore, slipped or came off, or if
you forgot to use one;
-
if you did not take your contraceptive pill as recommended.
You should take the tablet as soon as possible after sex, and within a
maximum of 5 days (120 hours).
This is because it is more effective if you take it as soon as
possible after unprotected sex.
This medicine is suitable for any woman of childbearing age, including
adolescents.
You can take the tablet at any time in the menstrual cycle.
ellaOne does not work if you are already pregnant
If your menstrual period is late, there is a possibility that you may
be pregnant. When your period is
late or when you have symptoms of pregnancy (heavy breasts, morning
sickness) you should consult a
doctor or other healthcare professional before taking the tablet.
If you have unprotected sex after taki
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ellaOne 30 mg tablet
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 30 mg ulipristal acetate.
Excipients with known effect
Each tablet contains 237 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
White to marble creamy, round curved tablet of 9 mm diameter engraved
with
_“еllа”_
on both sides.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Emergency contraception within 120 hours (5 days) of unprotected
sexual intercourse or contraceptive
failure.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The treatment consists of one tablet to be taken orally as soon as
possible, but no later than 120 hours
(5 days) after unprotected intercourse or contraceptive failure.
The tablet can be taken at any time during the menstrual cycle.
If vomiting occurs within 3 hours of the tablet intake, another tablet
should be taken.
If a woman’s menstrual period is late or in case of symptoms of
pregnancy, pregnancy should be
excluded before the tablet is administered.
_Special populations_
_ _
_Renal impairment_
No dose adjustment is necessary.
_Hepatic impairment _
In the absence of specific studies, no alternate dose recommendations
for ulipristal acetate can be
made.
_Severe hepatic impairment_
In the absence of specific studies, ulipristal acetate is not
recommended.
_Paediatric population _
There is no relevant use of ulipristal acetate for children of
prepubertal age in the indication
emergency contraception
_. _
3
Adolescents:
ulipristal acetate for emergency contraception is suitable for any
woman of child bearing age,
including adolescents. No differences in safety or efficacy have been
shown compared to adult women
aged 18 and older (see section 5.1).
Method of administration
Oral use.
The tablet can be taken with or without food.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1
4.4
SPECI
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 26-01-2024
Ciri produk Ciri produk Bulgaria 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 06-02-2015
Risalah maklumat Risalah maklumat Sepanyol 26-01-2024
Ciri produk Ciri produk Sepanyol 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 06-02-2015
Risalah maklumat Risalah maklumat Czech 26-01-2024
Ciri produk Ciri produk Czech 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Czech 06-02-2015
Risalah maklumat Risalah maklumat Denmark 26-01-2024
Ciri produk Ciri produk Denmark 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 06-02-2015
Risalah maklumat Risalah maklumat Jerman 26-01-2024
Ciri produk Ciri produk Jerman 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 06-02-2015
Risalah maklumat Risalah maklumat Estonia 26-01-2024
Ciri produk Ciri produk Estonia 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 06-02-2015
Risalah maklumat Risalah maklumat Greek 26-01-2024
Ciri produk Ciri produk Greek 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Greek 06-02-2015
Risalah maklumat Risalah maklumat Perancis 26-01-2024
Ciri produk Ciri produk Perancis 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 06-02-2015
Risalah maklumat Risalah maklumat Itali 26-01-2024
Ciri produk Ciri produk Itali 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Itali 06-02-2015
Risalah maklumat Risalah maklumat Latvia 26-01-2024
Ciri produk Ciri produk Latvia 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 06-02-2015
Risalah maklumat Risalah maklumat Lithuania 26-01-2024
Ciri produk Ciri produk Lithuania 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 06-02-2015
Risalah maklumat Risalah maklumat Hungary 26-01-2024
Ciri produk Ciri produk Hungary 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 06-02-2015
Risalah maklumat Risalah maklumat Malta 26-01-2024
Ciri produk Ciri produk Malta 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Malta 06-02-2015
Risalah maklumat Risalah maklumat Belanda 26-01-2024
Ciri produk Ciri produk Belanda 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 06-02-2015
Risalah maklumat Risalah maklumat Poland 26-01-2024
Ciri produk Ciri produk Poland 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Poland 06-02-2015
Risalah maklumat Risalah maklumat Portugis 26-01-2024
Ciri produk Ciri produk Portugis 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 06-02-2015
Risalah maklumat Risalah maklumat Romania 26-01-2024
Ciri produk Ciri produk Romania 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Romania 06-02-2015
Risalah maklumat Risalah maklumat Slovak 26-01-2024
Ciri produk Ciri produk Slovak 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 06-02-2015
Risalah maklumat Risalah maklumat Slovenia 26-01-2024
Ciri produk Ciri produk Slovenia 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 06-02-2015
Risalah maklumat Risalah maklumat Finland 26-01-2024
Ciri produk Ciri produk Finland 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Finland 06-02-2015
Risalah maklumat Risalah maklumat Sweden 26-01-2024
Ciri produk Ciri produk Sweden 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 06-02-2015
Risalah maklumat Risalah maklumat Norway 26-01-2024
Ciri produk Ciri produk Norway 26-01-2024
Risalah maklumat Risalah maklumat Iceland 26-01-2024
Ciri produk Ciri produk Iceland 26-01-2024
Risalah maklumat Risalah maklumat Croat 26-01-2024
Ciri produk Ciri produk Croat 26-01-2024
Laporan Penilaian Awam Laporan Penilaian Awam Croat 06-02-2015

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen